Telintra (ezatiostat)

News alerts, weekly reports and conference planners

Company:

MabVax

Drug class:

Glutathione S transferase inhibitor

‹

›

1year

Upregulation of GSTP1 mediated by chimeric TFE3 promotes TFE3-tRCC progression by targeting JNK signaling pathway. (PubMed, World J Surg Oncol)

Upregulation of GSTP1 mediated by chimeric TFE3 promotes TFE3-tRCC progression by targeting JNK signaling pathway, which underscore the potential of GSTP1 as a promising therapeutic target for TFE3-tRCC.

1 year ago

Journal

GSTP1 (Glutathione S-transferase pi 1) • TFE3 (Transcription Factor Binding To IGHM Enhancer 3) • ANXA5 (Annexin A5)

TFE3 translocation • TFE3 fusion

Telintra (ezatiostat)

over1year

Galangin alleviated Doxorubicin-induced cardiotoxicity by inhibiting ferroptosis through GSTP1/JNK pathway. (PubMed, Phytomedicine)

Gal could inhibit ferroptosis and protect against DIC through regulating the GSTP1/JNK pathway. Our research has identified a novel pathway through which Gal regulates DIC, providing valuable insights into the potential therapeutic efficacy of Gal in mitigating cardiotoxic effects.

over 1 year ago

Journal

GSTP1 (Glutathione S-transferase pi 1) • GPX4 (Glutathione Peroxidase 4) • PTGS2 (Prostaglandin-Endoperoxide Synthase 2) • SLC7A11 (Solute Carrier Family 7 Member 11) • MAPK8 (Mitogen-activated protein kinase 8) • PACERR (PTGS2 Antisense NFKB1 Complex-Mediated Expression Regulator RNA)

doxorubicin hydrochloride • Telintra (ezatiostat)

almost3years

Targeting GSTP1 as Therapeutic Strategy against Lung Adenocarcinoma Stemness and Resistance to Tyrosine Kinase Inhibitors. (PubMed, Adv Sci (Weinh))

Using patient-derived organoids from an ALK-translocated LUAD, the therapeutic potential of a specific GSTP1 inhibitor ezatiostat in combination treatment with the ALK inhibitor crizotinib is demonstrated. This study demonstrates GSTP1 to be a promising therapeutic target for long-term control of LUAD through targeting CSCs.

almost 3 years ago

Journal

GSTP1 (Glutathione S-transferase pi 1) • CAMK2A (Calcium/Calmodulin Dependent Protein Kinase II Alpha)

ALK translocation • GSTP1 overexpression

Xalkori (crizotinib) • Telintra (ezatiostat)